Metagenomi
Emeryville
About Metagenomi
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $457.0M
- Funding stage: IPO
- Last round: Series B (Jan 2023)
- Ticker: nasdaq:MGX
- Website: metagenomi.co
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Machine Learning, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/metagenomi-26461 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.